ARISE study: Study Design and Baseline Characteristics for a Phase 2 Trial of the Anti-Tau Antibody ABBV-8E12 in Progressive Supranuclear Palsy
Objective: This double-blind, placebo-controlled phase 2 study (M15-562 ARISE study, NCT02985879) assesses the safety and efficacy of ABBV-8E12 treatment in patients with progressive supranuclear palsy…Referral and diagnostic time intervals from symptom onset to death in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and Parkinson’s disease (PD)
Objective: To compare referral and diagnostic time intervals from index symptom to death in PSP/CBD and age-sex matched PD. Background: Misdiagnosis and delayed diagnosis are…PASSPORT, An Ongoing Phase 2 Study in Patients with PSP– Baseline Characteristics
Objective: To describe baseline characteristics of the participants with progressive supranuclear palsy (PSP) enrolled in the ongoing PASSPORT (NCT03068468) phase 2 study. Background: PSP is…Striatal FP-CIT SPECT findings for progressive supranuclear palsy subtypes
Objective: In our previous study FP-CIT SPECT (FP-CIT) in progressive supranuclear palsy-Parkinsonism (PSP-P) revealed higher anterior striatal accumulation, and PSP- Richardson’s syndrome (PSP-RS) revealed lower…Expanding the NINDS Parkinson’s Disease Biomarkers Program – Utilizing a Major Biomarker Resource to Address Atypical Parkinsonisms and Related Conditions
Objective: Expansion of a carefully curated resource for clinical and biosample data to address a critical need for biomarker discovery in Atypical Parkinsonisms and related…Open-label extension (OLE) of a multiple ascending dose (MAD) study of BIIB092 in participants with PSP: Safety analysis
Objective: To assess safety of BIIB092 in participants with progressive supranuclear palsy (PSP) in an OLE of a MAD study. Background: BIIB092 is a humanized…A longitudinal study of brain quantitative MRI analysis before and after diagnosis of progressive supranuclear palsy
Objective: We analyzed longitudinal change in MRI imaging in PSP from the period before clinical diagnosis. Six patients with clinically diagnosed PSP including 1 case…Comparative study of the cognitive and behavioral disturbances between progressive supranuclear palsy phenotypes
Objective: Explore cognitive and behavioural disturbances between subtypes of progressive supranuclear palsy (PSP). Background: Although clinical diagnosis of PSP is based on specific motor symptoms,…Striatal dopamine function in multiple system atrophy and progressive supranuclear palsy: A meta-analysis of imaging studies
Objective: To investigate differences in striatal presynaptic dopamine function between multiple system atrophy (MSA) and progressive supranuclear palsy (PSP) using combined data from all available…The characteristic of gait in progressive progressive supranuclear palsy
Objective: To elucidate the characteristic of gait in patients with progressive supranuclear palsy (PSP) and compare to healthy elderly and patients with Parkinson’s disease (PD)…
- « Previous Page
- 1
- …
- 35
- 36
- 37
- 38
- 39
- …
- 49
- Next Page »